Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

68.03 -1.41 (-2.03%)
Official Closing Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Via The Motley Fool
5 Stocks to Buy Now for Big Returns in 2025
Here are five stocks to buy now that could offer investors upside in 2025. 
Via The Motley Fool
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Not A Turnaround But Could Be Soon Novo Nordisk
On the weekly chart, NVO fell right down to the 200-week moving average. Clearly the leadership is showing a gross lack of leadership. 
Via Talk Markets
Topics Stocks / Equities
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss
Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and placebo over 72 weeks. 
Via Benzinga
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Though negotiated prices won't take effect until 2027, the inclusion of semaglutide has raised concerns about Novo's revenue and potential ripple effects on Eli Lilly's rival drugs. 
Via Stocktwits
Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts
The price negotiations will take place in 2025 and go into effect in 2027 for a new list of 15 drugs. 
Via Investor's Business Daily
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
Exposures Political
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Via The Motley Fool
Topics Government
Exposures Political
Is Novo Nordisk an Undervalued Stock to Buy Now?
Via The Motley Fool
What's Going on With Novo Nordisk Stock?
Via The Motley Fool
Better Buy: Novo Nordisk vs. AstraZeneca
Via The Motley Fool
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
The company cut its fourth-quarter guidance by 5%. But there's still a lot happening for Lilly. 
Via Investor's Business Daily
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
A cooler-than-expected December producer inflation report failed to ignite lasting gains on Wall Street Tuesday, reflecting lingering concerns about persistently high inflation among investors. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity
Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down. 
Via MarketBeat
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor. 
Via The Motley Fool
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets. 
Via Benzinga
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Via The Motley Fool
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60. 
Via Benzinga
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches. 
Via Benzinga
Investors Look Back at 2024
The S&P 500 had a great year. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
President-Elect Trump Poses Challenge To U.S. Tech Sales
Technology sales in the U.S. could reach a record level in 2025, if tariffs don't spoil the party, a tech futurist said at CES 2025. 
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, and the availability of approved alternatives. 
Via Benzinga
Exposures Product Safety
3 Trends To Watch
Hot topics for 2025 and why. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.